Business
Onco-Innovations Announces 90% of $0.60 Warrants Have Been Exercised
VANCOUVER, BC / ACCESS Newswire / August 15, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H, WKN: A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company") is pleased to announce the successful execution of a key component of its capital strategy, ...
About this update from Onco-innovations Ltd.
[{"type":"text","content":"VANCOUVER, BC / ACCESS Newswire / August 15, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H, WKN: A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company") is pleased to announce the successful execution of a key component of its capital strategy, as over 90% of the Company's outstanding common share purchase warrants priced at $0.60 have now, to date, been exercised, resulting in an additional inflow of capital and confirming the effectiveness of the Company's internal financing strategy.","length":525,"tagName":"p"},{"type":"text","content":"These warrant exercises, which took place over a period of eight months, support the Company's non-dilutive financing objectives. The Company believes this high conversion rate reflects strong shareholder alignment and growing market confidence in its long-term vision.","length":273,"tagName":"p"},{"type":"text","content":""Management is pleased that over 90% of the warrants priced at $0.60 have been exercised within an eight-month period. We believe this demonstrates our shareholders' belief in our strategic direction and reinforces the Company's ability to generate meaningful capital internally," stated Thomas O'Shaughnessy, CEO of Onco-Innovations.","length":356,"tagName":"p"},{"type":"text","content":"About Onco-Innovations Limited","length":30,"tagName":"p"},{"type":"text","content":"Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.","length":345,"tagName":"p"},{"type":"text","content":"ON BEHALF OF ONCO-INNOVATIONS LIMITED,","length":38,"tagName":"p"},{"type":"text","content":""Thomas O'Shaughnessy"Chief Executive Officer","length":60,"tagName":"p"},{"type":"text","content":"For more information, please contact:","length":37,"tagName":"p"},{"type":"text","content":"Thomas O'ShaughnessyChief Executive OfficerTel: + 1 888 261 [email protected]","length":100,"tagName":"p"},{"type":"text","content":"Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relati...